Roche Holding/Fr. ROP
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Roche Holding
- Ticker
- Fr. ROP
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 103,249
- Headquarters
- Basel, Switzerland
- Website
- www.roche.com
Roche Holding Metrics
BasicAdvanced
CHF 321B
26.22
CHF 15.33
0.33
CHF 9.80
2.44%
Price and volume
Market cap
CHF 321B
Beta
0.33
52-week high
CHF 404.40
52-week low
CHF 291.00
Average daily volume
1M
Dividend rate
CHF 9.80
Financial strength
Current ratio
1.228
Quick ratio
0.8
Long term debt to equity
0.728
Total debt to equity
0.908
Dividend payout ratio (TTM)
63.22%
Interest coverage (TTM)
18.24%
Profitability
EBITDA (TTM)
23,964
Gross margin (TTM)
74.17%
Net profit margin (TTM)
19.60%
Operating margin (TTM)
33.12%
Effective tax rate (TTM)
18.74%
Revenue per employee (TTM)
CHF 610,000
Management effectiveness
Return on assets (TTM)
13.51%
Return on equity (TTM)
38.11%
Valuation
Price to earnings (TTM)
26.216
Price to revenue (TTM)
5.083
Price to book
9.82
Price to tangible book (TTM)
57.26
Price to free cash flow (TTM)
23.033
Free cash flow yield (TTM)
4.34%
Free cash flow per share (TTM)
17.454
Dividend yield (TTM)
2.44%
Forward dividend yield
2.44%
Growth
Revenue change (TTM)
-0.83%
Earnings per share change (TTM)
30.57%
3-year revenue growth (CAGR)
0.23%
10-year revenue growth (CAGR)
2.01%
3-year earnings per share growth (CAGR)
3.87%
10-year earnings per share growth (CAGR)
3.82%
3-year dividend per share growth (CAGR)
1.04%
10-year dividend per share growth (CAGR)
1.92%
Bulls say / Bears say
Underlying growth remains solid: first-half sales rose 6% and core operating profit rose 10% at constant exchange rates. Roche reaffirmed its 2026 targets for mid-single-digit sales growth and high-single-digit core earnings growth. (Roche)
Roche’s obesity pipeline gained support from positive Phase II results for enicepatide in people with diabetes and excess weight, including 15.5% average weight loss at the highest dose after 48 weeks. Phase III studies are under way, so this remains a potential future growth driver rather than established revenue. (Roche)
A new Tecentriq indication creates a near-term commercial opportunity in stage III dMMR colon cancer. The FDA approval followed Phase III results showing a 50% lower risk of recurrence or death when Tecentriq was added to chemotherapy. (Roche)
Currency is obscuring the underlying improvement: first-half sales rose 6% at constant exchange rates but fell 2% in Swiss francs, while core earnings per share also declined in reported francs. A strong franc could therefore continue to weigh on CHF returns and reported results. (Roche)
Biosimilar competition continues to erode Roche’s older medicines: sales of products whose patents have expired fell 8% at constant exchange rates in the first half. Growth from newer products must keep outpacing this ongoing loss of revenue. (Roche)
China’s healthcare pricing reforms are weighing on Diagnostics growth. First-half sales growth was 3% at constant exchange rates, compared with 6% excluding the impact of the reforms, showing that policy pressure is still holding back the division. (Roche)
Data summarised monthly by Lightyear AI. Last updated on 11 Oct 2026.
Roche Holding Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Roche Holding
AllEURUSD
Fund name | Fund size | Fr. ROP weighting |
|---|---|---|
iShares MSCI Europe Health Care Sector€ESIH | €890M | 17.86% |
iShares MSCI Europe Health Care Sector£ESIH | €890M | 17.86% |
iShares STOXX Europe 600 Health Care€EXV4 | €709M | 17.04% |
iShares STOXX Europe 50€EXW3 | €141M | 7.41% |
iShares Edge MSCI Europe Momentum Factor£IEFM | €721M | 5.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.